Stellar Biotechnologies Inc (NASDAQ:SBOT) – Research analysts at Zacks Investment Research issued their FY2021 earnings per share (EPS) estimates for Stellar Biotechnologies in a report issued on Wednesday. Zacks Investment Research analyst B. Marckx anticipates that the biotechnology company will post earnings per share of ($0.51) for the year.
Stellar Biotechnologies (NASDAQ:SBOT) last issued its earnings results on Friday, December 1st. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. Stellar Biotechnologies had a negative net margin of 4,579.63% and a negative return on equity of 62.27%.
Shares of Stellar Biotechnologies (NASDAQ:SBOT) traded down $0.04 during trading hours on Thursday, hitting $0.80. 14,888 shares of the company’s stock were exchanged, compared to its average volume of 55,596. The firm has a market cap of $8.84, a price-to-earnings ratio of -1.67 and a beta of 0.51. Stellar Biotechnologies has a 52 week low of $0.75 and a 52 week high of $2.22.
ILLEGAL ACTIVITY NOTICE: “Stellar Biotechnologies Inc Expected to Post FY2021 Earnings of ($0.51) Per Share (SBOT)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/17/stellar-biotechnologies-inc-expected-to-post-fy2021-earnings-of-0-51-per-share-sbot.html.
About Stellar Biotechnologies
Stellar Biotechnologies, Inc is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases.
Receive News & Ratings for Stellar Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stellar Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.